Gyre Therapeutics, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed March 27, 2024. This is an annual report, not a standalone fourth-quarter report. Dollar figures are U.S. dollars.
Business context and reporting period
Gyre develops and commercializes small-molecule drugs for organ fibrosis. Its commercial business is primarily in China, led by ETUARY (pirfenidone) for idiopathic pulmonary fibrosis (IPF); its lead development candidate, F351, targets liver fibrosis. On October 30, 2023, the former Catalyst Biosciences completed a business combination that gave Gyre control of Beijing Continent Pharmaceuticals (doing business as Gyre Pharmaceuticals), renamed itself Gyre Therapeutics, and effected a 1-for-15 reverse stock split. Gyre indirectly owned 65.2% of Gyre Pharmaceuticals after the transaction.
Comparisons with 2022 require care: the transaction was accounted for as a reverse asset acquisition, with CPI treated as accounting acquirer and predecessor. 2023 also includes substantial transaction-related and nonrecurring charges.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $113.5 million | $102.3 million |
| Gross profit / gross margin | $108.8 million / 95.9% | $97.5 million / 95.3% |
| Operating income (loss) | $(67.2) million | $9.2 million |
| Net income (loss) | $(85.5) million | $4.3 million |
| Net income (loss) attributable to common stockholders | $(92.9) million | $2.3 million |
| Cash provided by operating activities | $25.9 million | $10.7 million |
| Cash used in investing activities | $(19.8) million | $(13.8) million |
| Cash provided by financing activities | $2.5 million | $0 |
- Revenue rose 10.9%, mainly from higher pharmaceutical product sales, partly offset by the absence of a $1.4 million licensing fee recognized in 2022. ETUARY sales were $112.1 million, up from $99.2 million; ETUARY represented 98.9% of total revenue in 2023.
- Selling and marketing expense increased 12.8% to $61.2 million. R&D expense fell 17.4% to $13.8 million, and general and administrative expense fell 15.6% to $14.7 million.
- The year’s loss included $83.1 million of acquired in-process R&D expensed in the business combination, a $9.3 million noncash warrant-liability fair-value expense, $2.7 million of divestiture losses, and a $0.6 million loss on disposal of property and equipment. Cash from operations was positive despite the reported loss, substantially reflecting noncash adjustments, including acquired IPR&D.
- At year-end, cash and cash equivalents were $33.5 million and long-term certificates of deposit were $23.4 million. Current assets were $57.2 million versus current liabilities of $20.0 million. Management said available cash, operating cash flows, and capital-market access were expected to fund operations and obligations for at least 12 months after filing.
- Total liabilities were $38.1 million. The filing does not identify material conventional borrowings; liabilities included $12.8 million of warrant liability and $4.7 million of CVR derivative liability. Convertible preferred stock of $64.5 million was classified outside stockholders’ equity as mezzanine equity, not as debt. Gyre reported total equity of $13.9 million, including $29.8 million of noncontrolling interest.
Material changes, outlook, and risks
- F351’s China Phase 3 trial for chronic hepatitis B-associated liver fibrosis completed enrollment of 248 patients in October 2023. The last patient out was expected in 2024, topline results by early 2025, and an NMPA application in early 2025, subject to results and regulatory review. F351 received China Breakthrough Therapy designation; this does not assure approval.
- For U.S. development, Gyre completed a Phase 1 F351 study in healthy volunteers and expected to submit an IND in late 2024, with a Phase 2a NASH-associated liver fibrosis trial planned for 2025, subject to IND clearance and China Phase 3 results. These are forward-looking plans, not financial guidance.
- ETUARY is also in Phase 3 studies for SSc-ILD, DM-ILD, and pneumoconiosis; enrollment for the SSc-ILD and DM-ILD studies remained ongoing, with no results available. F573’s Phase 2 trial for acute/acute-on-chronic liver failure began in March 2023. F230 was preclinical at year-end; an IND was submitted in China on March 13, 2024. F528 remained preclinical.
- Key risks include heavy dependence on ETUARY (98.9% of 2023 revenue), competition and potential pricing or reimbursement pressure in China, clinical and regulatory uncertainty, and the need to fund pipeline development. The five largest customers accounted for 85.5% of year-end trade receivables; the largest customer accounted for 50.5%.
- Other notable exposures include PRC currency-conversion and cross-border cash-transfer restrictions; concentration of operations and cash in China; reliance on third-party manufacturing for U.S. F351 trials and potential BIOSECURE Act/geopolitical impacts; and dependence on government grants and preferential tax treatment. Management reported no material cybersecurity incident identified in the last fiscal year and assessed disclosure controls and internal control over financial reporting as effective.
- GNI provided notice to convert all 13,151 preferred shares; conversion into 8,767,332 common shares became effective January 22, 2024. Year-end common shares outstanding were 76.6 million; the filing reports 85.4 million outstanding as of March 19, 2024. It also reports 18.3 million outstanding options and warrants convertible into 0.5 million common shares, creating potential dilution.
- Management does not anticipate cash dividends in the foreseeable future. The filing reports no material legal proceedings; two stockholder lawsuits related to the business combination were dismissed with prejudice in February 2024, and the company recorded a $0.4 million reimbursement of plaintiffs’ legal expenses.
Important facts for investors to verify
- Timing and results of F351’s China Phase 3 trial, planned NMPA submission, and U.S. IND and Phase 2a plans.
- ETUARY’s sales growth, market share, pricing, reimbursement status, and whether customer and receivables concentration has changed.
- Cash availability and operating cash generation, including how much cash is held in the PRC and is subject to transfer or conversion restrictions; assess funding needs against planned R&D and capital spending.
- Potential dilution from preferred-stock conversion, warrants, options, and any use of the $50 million at-the-market program.
- Whether the reported gross margin is sustainable and the effect of the one-time $83.1 million acquired IPR&D charge, warrant remeasurement, and business-combination accounting on comparisons.